Interpretation of Toxicokinetic and Pharmacokinetic Data in Safety Evaluation
Toxicokinetics (TK) and pharmacokinetics (PK) describe the absorption, distribution, metabolism, and excretion (ADME) of compounds, providing a quantitative understanding of systemic exposure. In preclinical toxicology, TK data are essential for interpreting dose–response relationships, identifying species differences, and establishing systemic exposure margins between animals and humans. These data form a foundational part of the IND-enabling safety package.
TK studies typically accompany toxicology studies, with plasma samples collected at multiple time points to determine parameters such as Cmax (peak concentration), Tmax (time to Cmax), AUC (area under the curve), half-life, clearance, and volume of distribution. The relationship between administered dose and systemic exposure allows assessment of dose linearity, saturation kinetics, and bioaccumulation.
Interpreting TK data involves comparing systemic exposures at the NOAEL to projected clinical exposures, ensuring adequate safety margins. When exposure in animals exceeds the anticipated human dose, findings are considered conservative; if not, additional studies may be required. Understanding tissue distribution also informs organ-specific toxicity, especially for compounds that accumulate in sensitive sites such as the liver, brain, or heart.
TK data are also essential for evaluating interspecies extrapolation, particularly in first-in-human dose prediction. Differences in metabolic pathways or transporter activity between rodents and humans can significantly affect systemic exposure. Using TK-informed modeling, such as physiologically-based pharmacokinetic (PBPK) approaches, enhances the accuracy of these projections.
Ultimately, the integration of TK and PK data with toxicology endpoints enables more precise risk assessment, optimized dosing strategies, and regulatory confidence in the safety margins of new therapeutics.